CN103462959B - Incarviatone A在制备治疗肝癌药物中的应用 - Google Patents

Incarviatone A在制备治疗肝癌药物中的应用 Download PDF

Info

Publication number
CN103462959B
CN103462959B CN201310432330.3A CN201310432330A CN103462959B CN 103462959 B CN103462959 B CN 103462959B CN 201310432330 A CN201310432330 A CN 201310432330A CN 103462959 B CN103462959 B CN 103462959B
Authority
CN
China
Prior art keywords
incarviatone
preparing
present
application
belongs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310432330.3A
Other languages
English (en)
Other versions
CN103462959A (zh
Inventor
张红丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Bodhi biological medicine science and Technology Co Ltd
Original Assignee
Wenzhou Chengqiao Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wenzhou Chengqiao Technology Co ltd filed Critical Wenzhou Chengqiao Technology Co ltd
Priority to CN201310432330.3A priority Critical patent/CN103462959B/zh
Publication of CN103462959A publication Critical patent/CN103462959A/zh
Application granted granted Critical
Publication of CN103462959B publication Critical patent/CN103462959B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了Incarviatone？A在制备治疗肝癌药物中的应用，属于药物新用途技术领域。本发明通过体外MTT抗肿瘤活性评价发现，Incarviatone？A对人肝癌细胞株HepG2、MHCC-LM3、Bel-7402和HuH-7的生长也具有显著的抑制作用。因此，Incarviatone？A能用于制备抗肝癌药物，具有良好的开发应用前景。本发明涉及Incarviatone？A在制备治疗肝癌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于肝癌细胞的抑制活性强得意想不到。

Description

Incarviatone A在制备治疗肝癌药物中的应用
技术领域
本发明涉及化合物IncarviatoneA的新用途，尤其涉及IncarviatoneA在制备抗肝癌药物中的应用。
技术背景
癌症是对人类生命健康危害最大的疾病之一，每年都有大量的人死于癌症。抗癌药物的研发一直是药学研究的热点。抗肿瘤药物中有74％是天然产物或其衍生物，如紫杉醇及其衍生物就是目前临床上应用效果比较好的抗肿瘤药物。因此，从天然产物中寻找抗癌化合物或先导化合物具有重要的意义。
本发明涉及的化合物IncarviatoneA是一个2012年发表(Shen,Y.H.etal.,2012.IncarviatoneA,astructurallyuniquenaturalproducthybridwithanewcarbonskeletonfromIncarvilleadelavayi,anditsabsoluteconfigurationviacalculatedelectroniccirculardichroicspectra.RSCAdvances2,4175–4180.)的新骨架化合物，该化合物拥有全新的骨架类型，目前没有关于该化合物活性方面的报道，对于本发明涉及的在制备治疗肝癌药物中的用途属于首次公开，而且由于骨架类型属于全新的骨架类型，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于肝癌的防治显然具有显著的进步。
发明内容
本发明提供化合物IncarviatoneA在制备抗肿瘤药物中的应用。
本发明采用如下技术方案：IncarviatoneA在制备抗肝癌药物中的应用，IncarviatoneA的结构式如式(Ⅰ)所示：
本发明通过体外MTT抗肿瘤活性评价发现，IncarviatoneA对人肝癌细胞株HepG2、MHCC-LM3、Bel-7402和HuH-7的生长也具有显著的抑制作用，抑制这4株细胞生长的IC50值分别为4.16±0.47μM、5.41±0.31μM、2.43±0.32μM和6.08±0.76μM。因此，IncarviatoneA能用于制备抗肝癌药物，具有良好的开发应用前景。
本发明涉及IncarviatoneA在制备治疗肝癌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于肝癌细胞的抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于肝癌的防治显然具有显著的进步。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
具体实施方式
本发明所涉及化合物IncarviatoneA的制备方法参见文献(Shen,Y.H.etal.,2012.IncarviatoneA,astructurallyuniquenaturalproducthybridwithanewcarbonskeletonfromIncarvilleadelavayi,anditsabsoluteconfigurationviacalculatedelectroniccirculardichroicspectra.RSCAdvances2,4175–4180.)。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
实施例1：本发明所涉及化合物IncarviatoneA片剂的制备：
取20克化合物IncarviatoneA，加入制备片剂的常规辅料180克，混匀，常规压片机制成1000片。
实施例2：本发明所涉及化合物IncarviatoneA胶囊剂的制备：
取20克化合物IncarviatoneA，加入制备胶囊剂的常规辅料如淀粉180克，混匀，装胶囊制成1000片。
下面通过药效学实验来进一步说明其药物活性。
实验例：采用MTT法评价化合物IncarviatoneA对人肝癌细胞株的生长抑制作用
1.方法：处于生长对数期的细胞：人肝癌细胞株HepG2、MHCC-LM3、Bel-7402和HuH-7(购买自中国科学院细胞库)以1.5×104浓度种于96孔板中。细胞培养24h贴壁后吸去原来的培养基。试验分为空白对照组、药物处理组。空白组更换含10％胎牛血清的1640培养基；药物处理组更换含浓度为100μM，50μM，10μM，1μM，0.1μM，0.01μM和0.001μM的IncarviatoneA的培养基。培养48h后，加入浓度5mg/mL的MTT，继续放于CO2培养箱培养4h，然后沿着培养液上部吸去100μL上清，加入100μLDMSO，暗处放置10min，利用酶标仪(Sunrise公司产品)测定吸光值(波长570nm)，并根据吸光值计算细胞存活情况，每个处理设6个重复孔。细胞存活率(％)＝ΔOD药物处理/ΔOD空白对照×100。
2.结果：IncarviatoneA对人肝癌细胞株HepG2、MHCC-LM3、Bel-7402和HuH-7的生长具有显著的抑制作用。该化合物抑制人肝癌细胞株HepG2、MHCC-LM3、Bel-7402和HuH-7生长的IC50值分别为：4.16±0.47μM、5.41±0.31μM、2.43±0.32μM和6.08±0.76μM。
由上述实施例表明，本发明的IncarviatoneA对人肝癌细胞株HepG2、MHCC-LM3、Bel-7402和HuH-7的生长具有很好的抑制作用。由此证明，本发明的IncarviatoneA具有抗肝癌活性，能用于制备抗肝癌药物。

Claims (1)

1.IncarviatoneA在制备治疗肝癌药物中的应用，所述化合物IncarviatoneA结构如式（Ⅰ）所示：
式（Ⅰ）。
CN201310432330.3A 2013-09-22 2013-09-22 Incarviatone A在制备治疗肝癌药物中的应用 Expired - Fee Related CN103462959B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310432330.3A CN103462959B (zh) 2013-09-22 2013-09-22 Incarviatone A在制备治疗肝癌药物中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310432330.3A CN103462959B (zh) 2013-09-22 2013-09-22 Incarviatone A在制备治疗肝癌药物中的应用

Publications (2)

Publication Number Publication Date
CN103462959A CN103462959A (zh) 2013-12-25
CN103462959B true CN103462959B (zh) 2015-12-02

Family

ID=49788157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310432330.3A Expired - Fee Related CN103462959B (zh) 2013-09-22 2013-09-22 Incarviatone A在制备治疗肝癌药物中的应用

Country Status (1)

Country Link
CN (1) CN103462959B (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021496A2 (en) * 2003-08-27 2005-03-10 The Trustees Of Columbia University In The City Of New York Synthesis of derivatives of ginkgolide c
EP1939166A1 (en) * 2006-12-19 2008-07-02 InterMed Discovery GmbH Plants extracts for use in brain modulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021496A2 (en) * 2003-08-27 2005-03-10 The Trustees Of Columbia University In The City Of New York Synthesis of derivatives of ginkgolide c
EP1939166A1 (en) * 2006-12-19 2008-07-02 InterMed Discovery GmbH Plants extracts for use in brain modulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ncarviatone A,a structurally unique natural product hybrid with a new carbon skeleton from Incarvillea delavayi,and its absolute configuration via calculated electronic circular dichroic spectra;Shen,Y.H.et al.,;《RSC ADVANCES》;20121231;4175-4180 *

Also Published As

Publication number Publication date
CN103462959A (zh) 2013-12-25

Similar Documents

Publication Publication Date Title
CN103463046B (zh) Lycojaponicumin A在制备治疗结直肠癌药物中的应用
CN103536598B (zh) 一种化合物在制备治疗肝癌药物中的应用
CN103462959B (zh) Incarviatone A在制备治疗肝癌药物中的应用
CN103463053B (zh) Lycojaponicumin A在制备治疗肝癌药物中的应用
CN103446150B (zh) Lycojaponicumin C在制备治疗肝癌药物中的应用
CN103405458B (zh) Chukrasone A在制备治疗肝癌药物中的应用
CN103446130B (zh) Lycojaponicumin B在制备治疗肝癌药物中的应用
CN103446089B (zh) Incarviatone A在制备治疗鼻咽癌药物中的应用
CN103462964B (zh) Incarviatone A在制备治疗胆管癌药物中的应用
CN103462966B (zh) Incarviatone A在制备治疗结直肠癌药物中的应用
CN103405444B (zh) Chukrasone A在制备治疗膀胱癌药物中的应用
CN103446133B (zh) Lycojaponicumin B在制备治疗舌癌药物中的应用
CN103446088B (zh) Incarviatone A在制备治疗皮肤癌药物中的应用
CN103405423B (zh) Chukrasone B在制备治疗肾癌药物中的应用
CN103463069B (zh) Lycojaponicumin C在制备治疗鼻咽癌药物中的应用
CN103462969B (zh) Incarviatone A在制备治疗乳腺癌药物中的应用
CN103479633B (zh) Lycojaponicumin B在制备治疗鼻咽癌药物中的应用
CN103446092B (zh) Incarviatone A在制备治疗宫颈癌药物中的应用
CN103446086B (zh) Incarviatone A在制备治疗胃癌药物中的应用
CN103463024B (zh) Lycojaponicumin B在制备治疗肾癌药物中的应用
CN103446091B (zh) Incarviatone A在制备治疗喉癌药物中的应用
CN103463017B (zh) Lycojaponicumin B在制备治疗胰腺癌药物中的应用
CN103463020B (zh) Lycojaponicumin A在制备治疗肾癌药物中的应用
CN103446144B (zh) Lycojaponicumin C在制备治疗胆管癌药物中的应用
CN103463078B (zh) Lycojaponicumin C在制备治疗肾癌药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Zhang Hongli

Inventor before: Jiang Chunping

Inventor before: Huang Rong

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20151103

Address after: 325011, building 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Zhejiang, Wenzhou

Applicant after: Wenzhou Chengqiao Technology Co.,Ltd.

Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings

Applicant before: Nanjing Guangkangxie Biomedical Technology Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20181219

Address after: 210000 No. 30 Central Road, Gulou District, Nanjing City, Jiangsu Province

Patentee after: Liu Huan

Address before: 325011 room 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Wenzhou, Zhejiang.

Patentee before: Wenzhou Chengqiao Technology Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190329

Address after: 233090 Zhongchuang Space A-43, 1st Floor, Chuangchuang Space, No. 8 Roadway 2595, Donghai Avenue, Bengbu City, Anhui Province

Patentee after: Bengbu Yongyuan Electronic Technology Co., Ltd.

Address before: 210000 No. 30 Central Road, Gulou District, Nanjing City, Jiangsu Province

Patentee before: Liu Huan

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20191211

Address after: 239000 room 1602 and 1604, 3 building, 82 business center, Huayuan Road, Chuzhou, Anhui.

Patentee after: Anhui Bodhi biological medicine science and Technology Co Ltd

Address before: 233090 Zhongchuang Space A-43, 1st Floor, Chuangchuang Space, No. 8 Roadway 2595, Donghai Avenue, Bengbu City, Anhui Province

Patentee before: Bengbu Yongyuan Electronic Technology Co., Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151202

Termination date: 20200922

CF01 Termination of patent right due to non-payment of annual fee